Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)

This “allocated fund in clinical research” was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years.

News & Events

Posted on

The first TANDEM grant call received 28 applications from clinician-basic researcher pairs across Switzerland, each jointly addressing a question of…

Read more
Posted on

See our Annual Report 2021 !

Read more
Posted on

The ISREC Foundation has been promoting cancer research since 1964. The work accomplished by the supported scientists over the past decades has led to…

Read more
Posted on

As part of her “Hans Tuppy Lecture” at the University of Vienna, attended by Prof. Tuppy himself, an interview was conducted with Prof. Susan Gasser.…

Read more